跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XEVUDY 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
XEVUDY 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Approved
STANDARD
XEVUDY 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Glaxosmithkline Trading Services Limited
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Dec 23, 2021
Approval ID
b433838ebf7ac732
Company
Glaxosmithkline Trading Services Limited
Type
Standard
Approval Details
Approval Id
b433838ebf7ac732
Drug Cima Aemps Name
XEVUDY 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Register Number
1211562001
Holder Company Name
Glaxosmithkline Trading Services Limited
Marketing Company Name
Glaxosmithkline S.A.
Holder Company Detail Path
/organization/glaxosmithkline-trading-services-limited
Marketing Company Detail Path
/organization/glaxosmithkline-sa
Authorization Date
2021-12-23
Dosage Form
CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN
Dose
500 mg
Route Of Administration
VÍA INTRAVENOSA
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Glaxosmithkline Trading Services Limited
Company Detail Path
/organization/glaxosmithkline-trading-services-limited
Company Information
Pharmaceutical Company Name
GLAXOSMITHKLINE TRADING SERVICES LIMITED
Country Name
Spain
City Name
madrid,madrid,country_es
Address
PASEO CASTELLANA 11
Active Ingredients
SOTROVIMAB
62,5 mg/ml
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Dec 23, 2021
Approval ID
b433838ebf7ac732
Type
Standard
Back to CIMA-AEMPS Approvals